Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider David Y. Liu sold 7,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $16.97, for a total value of $118,790.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of Protagonist Therapeutics, Inc. (NASDAQ PTGX) traded down $0.39 during midday trading on Wednesday, hitting $16.57. The stock had a trading volume of 108,200 shares, compared to its average volume of 83,662. Protagonist Therapeutics, Inc. has a 1-year low of $8.00 and a 1-year high of $26.36.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Monday, November 6th. The company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.40. The firm had revenue of $8.78 million during the quarter. sell-side analysts predict that Protagonist Therapeutics, Inc. will post -3.66 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Protagonist Therapeutics, Inc. (PTGX) Insider David Y. Liu Sells 7,000 Shares” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/15/protagonist-therapeutics-inc-ptgx-insider-david-y-liu-sells-7000-shares.html.

A number of large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN boosted its position in Protagonist Therapeutics by 60.8% during the 3rd quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock valued at $169,000 after purchasing an additional 3,617 shares during the period. First Manhattan Co. acquired a new position in Protagonist Therapeutics during the 3rd quarter valued at approximately $293,000. California State Teachers Retirement System boosted its position in Protagonist Therapeutics by 8.5% during the 2nd quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after purchasing an additional 1,300 shares during the period. State Street Corp boosted its position in Protagonist Therapeutics by 20.9% during the 2nd quarter. State Street Corp now owns 112,474 shares of the company’s stock valued at $1,270,000 after purchasing an additional 19,411 shares during the period. Finally, Senzar Asset Management LLC acquired a new position in Protagonist Therapeutics during the 2nd quarter valued at approximately $3,094,000. Institutional investors and hedge funds own 39.73% of the company’s stock.

A number of equities research analysts have recently weighed in on PTGX shares. BTIG Research started coverage on Protagonist Therapeutics in a report on Friday, July 21st. They issued a “buy” rating and a $36.00 price target for the company. Zacks Investment Research upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. ValuEngine upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Finally, BMO Capital Markets lowered their price target on Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating for the company in a report on Thursday, October 19th.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Receive News & Stock Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related stocks with our FREE daily email newsletter.